How do you manage immune-related toxicity from checkpoint inhibitors that is refractory to initial steroid therapy?

Consensus guidelines recommend the use of steroid therapy for immune related adverse events irAE, and fortunately most toxicities (with the exception of endocrinopathies) are reversible. No prospective data exists on the management of irAE, including steroid refractory irAE. In most cases, we use in...